Immune Therapeutics Clears Critical Regulatory Hurdle for Lodonal in Kenya

Immune Therapeutics Clears Critical Regulatory Hurdle for Lodonal in Kenya

ORLANDO, Fla., April 17, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM, its proprietary formulation of lower-dose naltrexone, announced today that the Dominican Republic Ministry of Public Health has granted Immune's request to export Lodonal to Kenya.

Immune Therapeutics formulates and manufactures Lodonal in the Dominican Republic. Local laws require a Certificate of Pharmaceutical Product ("COPP") to export Lodonal to Kenya.

Read More
Immune Therapeutics Clears Critical Regulatory Hurdle for Lodonal in Kenya

Immune Therapeutics Clears Critical Regulatory Hurdle for Lodonal in Kenya

ORLANDO, Fla., March 17, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using Lodonal™, its proprietary formulation of lower-dose naltrexone, announced today that the Dominican Republic Ministry of Public Health has granted Immune's request to export Lodonal to Kenya.

Read More
Immune Therapeutics, Inc. Further Strengthens Balance Sheet as it Prepares for Commercialization

Immune Therapeutics, Inc. Further Strengthens Balance Sheet as it Prepares for Commercialization

Highlights:

- Company Redeems Nearly All Outstanding Convertible Debentures
- Replaces Nearly $650,000 of Long-Term Debt with Financing on Significantly Better Terms from a Strategic Long-Term Institutional Investor
- Company’s Latest Strategic Financial and Operational Initiatives Prepares Immune for Commercialization of its Blockbuster Drug Lodonal™
- Company On-Track Towards Achieving Cash Flow Positive Status in First Half 2017 and Profitability by Fiscal Year-End
- Following Launch of Lodonal, Management to Provide Greater Detail Over Pipeline of its Various Drugs in the Approval Process both with the FDA and Internationally
- Management to Update Shareholders on Better than Expected Progress Shortly

Read More